Skip to main content
GemVax & KAEL Co.,Ltd. logo

GemVax & KAEL Co.,Ltd. — Investor Relations & Filings

Ticker · 082270 ISIN · KR7082270000 KO Manufacturing
Open in API
Filings indexed 647 across all filing types
Latest filing 2025-07-11 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 082270

About GemVax & KAEL Co.,Ltd.

https://gemvax.com/

GemVax & KAEL is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics. Its lead drug candidate is GV1001, a synthetic peptide composed of 16 amino acids, which has demonstrated multiple actions including the modulation of neuroinflammation and reduction of oxidative stress. The company's development pipeline primarily targets neurodegenerative diseases, such as Alzheimer's disease and Progressive Supranuclear Palsy (PSP). Other therapeutic areas under investigation include pancreatic cancer and benign prostatic hyperplasia. GemVax & KAEL is actively advancing its programs through clinical trials to evaluate the efficacy and safety of its novel treatments.

Recent filings

Filing Released Lang Actions
[기재정정]주요사항보고서(신주인수권부사채매수선택권행사자지정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed by GemVax & Kael regarding the designation of an exerciser for a stock option (call option) attached to a bond with warrants (BW). It details the correction of a previously submitted report, specifically updating the designation date and the list of entities/individuals involved in the call option. This type of regulatory filing concerning capital structure, specifically the exercise of call options on bonds, falls under the 'Regulatory Filings' category as it is a specific corporate disclosure required by the financial authorities.
2025-07-11 Korean
주요사항보고서(신주인수권부사채매수선택권행사자지정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) filed with the Financial Services Commission (금융위원회) in South Korea. It details the designation of persons exercising a call option (매수선택권) regarding Bonds with Warrants (BW). This type of filing relates to capital structure changes and financing activities, specifically the exercise of call options on debt instruments. In the provided taxonomy, this falls under 'Capital/Financing Update' (CAP) as it pertains to the company's financing activities and capital structure adjustments.
2025-07-10 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (Non-Deal Roadshow). It provides details such as the date, location, target audience, and purpose of the meeting. It is not the presentation itself, but an announcement of the event and the availability of materials. Therefore, it falls under the category of a regulatory filing announcement regarding an event.
2025-07-01 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share transactions (disposal of shares) by an executive (Kwak Sohyun) of GemVax & Kael. This is a standard regulatory filing for insider trading/director dealings in the Korean market, which corresponds to the 'Director's Dealing' category.
2025-07-01 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership, special relationships, and collateral/pledge agreements for (주)젬백스앤카엘. This type of filing is specifically categorized as a 'Major Shareholding Notification' (MRQ) in the provided schema.
2025-07-01 Korean
[기재정정]최대주주변경을수반하는주식담보제공계약체결
Major Shareholding Notification Classification · 100% confidence The document is a regulatory filing regarding a 'Change in Maximum Shareholder's Stock Collateral Agreement' (최대주주 변경을 수반하는 주식 담보제공 계약 체결). It details specific collateralized loan agreements, debt amounts, and the nature of the security provided by the major shareholder. This type of disclosure is a standard regulatory requirement for listed companies in Korea (DART system) to inform the market about significant changes in the financial structure or potential ownership risks related to the major shareholder. It does not fit into specific categories like Earnings Release, Annual Report, or M&A, and is best classified as a Regulatory Filing.
2025-06-24 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.